Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017


19.06.17 15:30
Meldung
 
Helén Tuvesson new CEO of <strong>Active Biotech</strong> AB from July 1, 2017

PRESS RELEASE

Lund - Active Biotech AB (Nasdaq Stockholm: ACTI) today announces that the Board has appointed the company's current CSO Helén Tuvesson as new CEO of Active Biotech AB. Helén Tuvesson will take up the position on July 1, 2017, replacing Tomas Leanderson, who has been the company's CEO since 2008.



Helén Tuvesson has a broad experience in drug development after more than 20 years in the pharmaceutical industry. Helén has held various senior positions in Active Biotech and since 2011 she has been responsible for the company's research and development.



"I am proud and glad that in Helén Tuvesson we have an internal candidate who can take responsibility as CEO, ensuring continuity and a controlled handover. Helén has been instrumental in the structural changes made in the company during 2016/2017 and has a solid industry experience. I am convinced that she has the qualities required to shape the company's future strategy and maximize its opportunities," says Mats Arnhög, Chairman of the Board.



"I would also like to thank Tomas Leanderson for his significant contribution to the company's business for a long period. Tomas Leanderson will be at the company's disposal during a transitional period," said Mats Arnhög.



"I am very happy and at the same time humbled for the confidence to lead Active Biotech further. I am well acquainted with the company's projects and its potential and look forward to developing the portfolio further and creating value for the company," says Helén Tuvesson.

Lund June 19, 2017

Active Biotech AB (publ)

For further information, please contact:

Mats Arnhög

Chairman of the Board

Tel +46 8 54503770

Mobil: +46 705 915096

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/ inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund, Sweden

Tel: +46 (0)46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 15.30 a.m. CET on June 19, 2017.

Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017






This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Globenewswire




 

Breaking News


Kurs- und weitere Informationen zum Thema:

Active Biotech

Aktuelle Diskussionen zum Thema:

Active Biotech - Rebound alter ... (08.05.17)

Aktuelle Nachrichten zum Unternehmen:

Active Biotech AB bricht nach en. (01.08.11)
Active Biotech bricht nach enttäus. (01.08.11)
Evotec und Active Biotech vereinb. (06.06.11)
Evotec und Active Biotech unterze. (11.03.10)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Active Biotech
Weitere Meldungen
 
20.06 Nokia Bell Labs first to sho.
20.06 Nordic Mines AB (publ) noti.
20.06 Galapagos' R&D Update 201.
20.06 Van Lanschot Kempen: upda.
20.06 Novartis RTH258 (brolucizum.
20.06 Novartis real world study sh.
20.06 Intertrust N.V. announces c.
20.06 Takeda and TiGenix announc.
20.06 NEOVACS ANNOUNCES TH.
20.06 Ad hoc: SINGULUS TECHNO.
19.06 Ad hoc: SANHA plant Prolo.
19.06 NN Group announces stock .
19.06 Ad hoc: Bastei Lübbe AG: .
19.06 Regulated information - Age.
19.06 Ad hoc: WILEX AG: Tochte.
19.06 Volta Finance Limited : Dire.
19.06 GOGL - Delivery of dry bul.
19.06 Songa Offshore SE : Manda.
19.06 Nets A/S: Final transactions.
19.06 The valuation of Mandatum .
19.06 Helén Tuvesson new CEO o.
19.06 NADL - Announces contract.
19.06 Ad hoc: CropEnergies erhöh.
19.06 Ad hoc: ICHOR Coal N.V.: .
19.06 187,133 Orion Corporation A.
19.06 Ad hoc: Bestandsentwickler .
19.06 Ad hoc: paragon AG beschl.
19.06 Marathon Asset Managemen.
19.06 Ad hoc: Ad-hoc: Preisspann.
19.06 EQS-Adhoc: Conzzeta: Stark.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 24630 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Solarworld: Es wird dramatisch!
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
DAX - Bald tiefer im ...
Philip Hopf, Hopf Klinkmüller Capital. (19:05)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
S&P-500-Index - Short-...
Christian Zoller, www.boerse-daily.de (17:14)
Experte: Christian Zoller, www.boerse-daily.de
DAX kehrt bei 12.300 ...
CMC Markets, (17:01)
Experte: CMC Markets,
Paion: 3-Stufen-Analyse ...
Robert Sasse, (16:50)
Experte: Robert Sasse,
Nordex-Aktie: Wie stehen ...
Volker Gelfarth, (16:25)
Experte: Volker Gelfarth,
Volatiler Dax – US-Politik, ...
Cornelia Frey, Börse Stuttgart AG (15:38)
Experte: Cornelia Frey, Börse Stuttgart AG
Lucapa Diamond: Und ...
Björn Junker, GOLDINVEST.de (14:59)
Experte: Björn Junker, GOLDINVEST.de
Börsengeflüster ...
WIRTSCHAFTSINFORM., (14:38)
Experte: WIRTSCHAFTSINFORMATION .,
Weich gelandet
Ralf Flierl, Smart Investor (14:25)
Experte: Ralf Flierl, Smart Investor
Orangensaft: Saisonalität ...
Jürgen Sterzbach, boerse-daily.de (13:11)
Experte: Jürgen Sterzbach, boerse-daily.de
DAX-Unternehmen: Rekorde ...
Sven Weisenhaus, Stockstreet GmbH (12:35)
Experte: Sven Weisenhaus, Stockstreet GmbH
Osram nach Siemens-...
Feingold-Research, (12:08)
Experte: Feingold-Research,
Niquet's World
Neues vom Portal
 
Globale Finanzmärkte auf dem Prüfstand
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen